- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHINA YONGXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 61,16 | +1,49 % | Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on pipeline strength | ||
| CSPC PHARMA | 1,063 | +4,52 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2070 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE ... | ||
| SELLAS LIFE SCIENCES | 1,666 | +1,59 % | Sellas Life Sciences files to sell 19.69M shares of common stock for holders | ||
| ACADIA PHARMACEUTICALS | 17,285 | +0,12 % | Mizuho maintains Neutral rating on Acadia Pharmaceuticals stock ahead of Q3 | ||
| CATALYST PHARMACEUTICALS | 17,990 | +2,54 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 376,80 | +1,92 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,058 | -0,86 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,698 | +0,83 % | Opus Genetics, Inc.: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) | Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| SAVARA | 2,980 | +2,76 % | Savara Inc.: Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 | - The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% - - Changes in DLco%, the Primary Endpoint in IMPALA-2, Were... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 4,160 | +2,46 % | GALECTIN THERAPEUTICS INC - 8-K, Current Report | ||
| BIODEXA PHARMACEUTICALS | 9,490 | 0,00 % | Biodexa Pharmaceuticals PLC: Interim results for the six months ended June 30, 2025 | September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,225 | 0,00 % | NovaBay Pharmaceuticals: CEO David Lazar tritt nach Aktienübertragungsvereinbarung zurück | ||
| NEURIZON THERAPEUTICS | 0,071 | +1,44 % | Neurizon Therapeutics Limited: FDA Lifts Clinical Hold on NUZ-001 | Highlights:
U.S. FDA lifts the Clinical Hold on NUZ-001, Neurizon®'s lead investigational therapy for ALS
Clears the way for entry into... ► Artikel lesen |
Das Unternehmen CHINA YONGXIN PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA YONGXIN PHARMACEUTICALS INC finden Sie auf Wallstreet Online.